TCT-48 Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial): Very Late Device Thrombosis While on Extended DAPT

Volume: 74, Issue: 13
Published: Oct 1, 2019
Abstract
The COMPARE-ABSORB trial has shown noninferiority between the bioresorbable vascular scaffold (BVS) and the metallic everolimus-eluting stents (EES) at 1 year in composite safety and effectiveness outcomes, although BVS carries a higher device thrombosis rate than EES. Several studies indicated...
Paper Details
Title
TCT-48 Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial): Very Late Device Thrombosis While on Extended DAPT
Published Date
Oct 1, 2019
Volume
74
Issue
13
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.